Creatine is one of the most popular, legal ergogenic agents.
Recently, researchers led by Robin da Silva 1 checked whether creatine affects non-alcoholic fatty liver disease (NAFLD). NAFLD is a disease associated with hepatic steatosis, as evidenced by imaging or histological examination.
The study was published in The Journal of Nutritional Biochemistry in December 2017.
In rats fed a high-fat diet with creatine, the effect of supplementation on the rate of lipoprotein formation, mitochondrial functions and increased oxidative potential (increased lipid consumption) were noted. In rats with fatty liver, creatine stopped the accumulation of lipids!
Confirm previous observations that liver cells (in in vitro tests) secrete and oxidize more oleic acid. Thus, creatine can effectively change the hepatic lipid metabolism by increasing the secretion of lipoproteins and increased oxidation.
Can creatine be an effective therapy for NAFLD? It takes much more well-controlled studies in humans to confirm this. Researchers say it has such an effect.